DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLOPATADINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Olopatadine Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00331500	Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis	Completed	Alcon Research	Phase 3	The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.
NCT00389025	Mast-Cell Stabilizing Effects of Olopatadine	Completed	Alcon Research	Phase 4	To assess the effects of olopatadine of the release of mast cell histamine
NCT00489398	Comparison of CL Wear Between Two Allergy Drops	Withdrawn	Merck Sharp & Dohme Corp.	Phase 4	Comparison of two allergy drops for enhancing comfort and performance of contact lens wear
NCT00489398	Comparison of CL Wear Between Two Allergy Drops	Withdrawn	Hom, Milton M., OD, FAAO	Phase 4	Comparison of two allergy drops for enhancing comfort and performance of contact lens wear
NCT00578331	Safety Study of Olopatadine Nasal Spray	Completed	Alcon Research	Phase 3	The purpose of this study is to determine whether olopatadine nasal spray is safe and effective when used for up to one year by patients with perennial allergic rhinitis.
NCT00578929	Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients	Completed	Alcon Research	Phase 3	A study to demonstrate the superiority of test article nasal spray relative to vehicle nasal spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6 to 11 years with a history of seasonal allergic rhinitis.
NCT00609128	Allergic Eye Disease Tear Mediators	Unknown status	University of Wisconsin, Madison	N/A	The purpose of the research is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem with symptoms of temporary redness, itching, tearing, and swelling of the eyes. Substances released by cells in the affected tissues cause allergic reactions in the eye and elsewhere in the body.

Clinical Trial Conditions for Olopatadine Hydrochloride

Condition Name

Condition Name for Olopatadine Hydrochloride
Intervention	Trials
Allergic Conjunctivitis	18
Seasonal Allergic Rhinitis	5
Conjunctivitis, Allergic	5
Allergic Rhinitis	4

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Olopatadine Hydrochloride
Intervention	Trials
Conjunctivitis, Allergic	27
Conjunctivitis	26
Rhinitis	14
Rhinitis, Allergic	13

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Olopatadine Hydrochloride

Trials by Country

Trials by Country for Olopatadine Hydrochloride
Location	Trials
United States	57
Japan	4
Canada	4
India	2
Croatia	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Olopatadine Hydrochloride
Location	Trials
Texas	9
Massachusetts	4
Tennessee	3
Wisconsin	3
Illinois	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Olopatadine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Olopatadine Hydrochloride
Clinical Trial Phase	Trials
Phase 4	19
Phase 3	13
Phase 2	5

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Olopatadine Hydrochloride
Clinical Trial Phase	Trials
Completed	33
Recruiting	3
Withdrawn	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Olopatadine Hydrochloride

Sponsor Name

Sponsor Name for Olopatadine Hydrochloride
Sponsor	Trials
Alcon Research	20
Allergan	3
Merck Sharp & Dohme Corp.	2

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Olopatadine Hydrochloride
Sponsor	Trials
Industry	35
Other	9

Export unavailable in trial.
Subscribe for complete access.